Sara Hurvitz, MD is Assistant Clinical Professor of Medicine at the University of California, Los Angeles; Co-Director, Santa Monica-UCLA Outpatient Oncology Practice; Medical Director, Clinical Research Unit, Jonsson Comprehensive Cancer Center; and Director, Breast Oncology Program, Division of Hematology-Oncology. She is a co-author of HER2-Positive Breast Cancer.
Dr. Hurvitz received her MD from the Keck School of Medicine of University of Southern California, after which she was Chief Resident and performed a fellowship in Hematology/Oncology at UCLA School of Medicine. She is board certified in Internal Medicine and Medical Oncology.
Dr. Hurvitz is a member of numerous professional organizations including the American Society of Clinical Oncology and the American Association of Cancer Research. Her research interests include the preclinical and clinical evaluation of cutting-edge targeted therapies for breast cancer including novel therapeutic combinations. She has served as principal investigator for over 20 phase I, II, and III international breast cancer clinical trials and has presented the results of her breast cancer research at multiple national and international symposiums. She has also been active in community service, breast cancer advocacy, and patient education.
Dr. Hurvitz has received numerous honors, including a Young Investigator Award from the American Society of Clinical Oncology as well as the Marni Levine Breast Cancer Research Award and the Andrea Dembrowsky Breast Cancer Research Award. She is a frequent invited speaker at academic grand rounds, national and international medical symposia, and serves as a reviewer for numerous medical journals. She is also the author or coauthor of articles that have appeared in peer-reviewed journals including Journal of Clinical Oncology, Lancet Oncology, and Clinical Cancer Research, as well as many abstracts and several book chapters.
Leave A Comment